Washington Clinical Trials Report — June 2026

For Washington residents considering participation in clinical research, June 2026 presents a crucial window of opportunity, especially for those looking to enroll in trials nearing their conclusion. A total of 88 clinical trials across the state are slated to close within the next 90 days, meaning interested individuals should act quickly to explore these options. This urgent call includes 13 studies that are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Patients living with certain health challenges should also be aware of trials with impending deadlines. Research focusing on various cancers, neurological conditions, and infectious diseases are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Major depressive disorder (3 trials)
• Metastatic malignant solid neoplasm (2 trials)
• Breast cancer (2 trials)
• Leukemia, myeloid (2 trials)
• Prostate cancer (2 trials)
• Refractory hematologic malignancy (2 trials)
• Crohn's disease (2 trials)
• Advanced solid tumor (2 trials)
• HIV infections (2 trials)
• Leukemia (2 trials)

New Horizons: Breakthrough Trials Launching in Washington

This month marks a significant expansion in Washington's clinical research landscape, with 35 new trials opening their doors – a notable increase from the 28 trials that began in May 2026. These new studies include several high-profile Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraine.

Among the most impactful new studies are:

• Novo Nordisk A/S is sponsoring NCT07627074, a real-world study titled "Weight Loss in Adults Using Semaglutide." This observational study aims to enroll a massive 35,000 participants to assess weight loss outcomes when commercially available semaglutide is used in routine clinical practice.
• For those with obesity or overweight and a weight-related comorbidity, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is leading NCT07654361, a Phase 3 study called "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This global, randomized, placebo-controlled trial seeks 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron.
• AstraZeneca is launching two significant Phase 3 trials for type 2 diabetes mellitus. NCT07662109 will investigate "The Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus," targeting 2,000 participants. Additionally, NCT07662213, also sponsored by AstraZeneca, seeks 1,200 participants to compare elecoglipron with oral semaglutide in adults with type 2 diabetes and increased cardiovascular risk.
• Migraine sufferers may find an opportunity in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This Phase 3, double-blind, randomized study sponsored by Kallyope Inc. aims to enroll 1,800 participants.
• Another important Phase 3 study from Gasherbrum Bio, Inc. is NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This randomized, double-blind, placebo-controlled study will assess aleniglipron in 1,100 participants.
• Beyond drug trials, the University of British Columbia is sponsoring NCT07629154, "Smart Discharges for Older Children," an observational study with 4,000 participants aiming to build algorithms to identify children at risk of mortality after discharge in East Africa.
• The RTI International is leading NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," a long-term observational study following 1,400 people with Down syndrome of all ages to better understand their health and development.

Expanding Research for Key Health Conditions

The 35 new trials opening this month in Washington cover a diverse array of health conditions, with a strong emphasis on metabolic health. The most common conditions addressed by these new studies include:

• Obesity (6 trials)
• Overweight (5 trials)
• Type 2 diabetes mellitus (4 trials)
• Multiple sclerosis (2 trials)
• Migraine (2 trials)
• Chronic pain (2 trials)
• Acute myeloid leukemia (2 trials)
• Chronic weight management (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 19 of the new studies. Procedure-based research is also well-represented with 7 new trials, alongside other types of research including behavioral interventions, medical devices, and biological treatments.

Washington's Research Footprint: Where to Find Trials

Washington's clinical research landscape is robust, with a total of 1,672 clinical trials currently recruiting across 66 cities and 801 research sites statewide. While opportunities are widely available, this month's new research initiatives show a clear concentration in the state's major metropolitan areas. Seattle continues to be a central hub, welcoming 22 new trials. Renton also saw significant activity with 9 new trials. Other cities expanding their research offerings include:

• Bellevue (2 new trials)
• Redmond (1 new trial)
• Kirkland (1 new trial)
• Spokane (1 new trial)
• Tacoma (1 new trial)
• Vancouver (1 new trial)

This distribution ensures that while major cities lead in the volume of new studies, residents in various regions of Washington still have access to cutting-edge research opportunities.

Opportunities for All: Healthy Volunteers and Diverse Participation

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical science. Of the 35 new trials launched this month, 3 are actively seeking healthy volunteers. Statewide, a total of 141 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Washington are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 6 include children as participants, and a significant 32 include older adults, ensuring that research benefits diverse age groups. Only 1 new trial is male-only, with no female-only trials opening this month.

Academic institutions continue to play a vital role in the state's research ecosystem, with the University of Washington sponsoring 10 of the new trials, and Fred Hutchinson Cancer Center sponsoring 3. Industry sponsors are also driving significant research efforts, with 19 new trials sponsored by pharmaceutical companies such as AstraZeneca, Novo Nordisk A/S, Gasherbrum Bio, Inc., Kallyope Inc., and Eli Lilly and Company. These industry-led studies represent a substantial portion of the new research, signaling a strong focus on developing new drugs and treatments.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Washington.